Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6428MR)

This product GTTS-WQ6428MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6428MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7911MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ11407MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ13557MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ6877MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ11590MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ8643MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ3442MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ12788MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-59R5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW